Basilea and Pfizer Collaborated to Commercialize Cresemba for Invasive Aspergillosis and Mucormycosis
Shots:
- Under the 2017 agreement, Basilea received $72.64M up front & ~$427M upon achievement of pre-specified regulatory & sales milestones along with royalties & continues to focus on forming new partnerships for the commercialization of Cresemba & Zevtera globally
- In the recent updated 2017 agreement, Basilea received $1.25M in sales milestones in the Asia Pacific region & is eligible to receive the remaining regulatory & sales milestone of ~$569.36M along with royalties
- Isavuconazole was approved in 68 countries under the trade name Cresemba & also approved for invasive aspergillosis & mucormycosis in the 27 EU member states, Iceland, Liechtenstein, Norway & UK. Basilea has entered into multiple agreements for isavuconazole in the US & other countries
Ref: Globe Newswire | Image: Basilea
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
